...
首页> 外文期刊>World Journal of Oncology >Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
【24h】

Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation

机译:淋巴细胞与单核细胞的比率和改良的格拉斯哥预后评分可预测无驱动突变的肺腺癌的预后

获取原文
           

摘要

Background: Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) and modified Glasgow prognostic score (mGPS) are useful prognostic markers based on host-related systemic inflammatory response. They have been shown as independent prognostic biomarkers in various cancers, including non-small cell lung cancer. However, there has been little evidence for a specific population of pulmonary adenocarcinoma without active epidermal growth factor receptor (EGFR) mutation.Methods: We retrospectively reviewed 159 patients who met the following criteria: histologically or cytologically diagnosed adenocarcinoma, confirmed wild-type EGFR, started first-line cytotoxic chemotherapy between July 2007 and March 2017 at our hospital, and c-stage IIIB or IV. We compared overall survival (OS) between dichotomized groups by the optimal cut-off points of NLR and LMR, and mGPS 0 - 1 vs. 2. Univariate and multivariate Cox proportional hazard analyses also detected prognostic factors for OS.Results: As favorable prognostic factors for OS, multivariate analysis detected Eastern Cooperative Oncology Group performance status (ECOG PS) 0 - 1 (hazard ratio (HR) 3.43, 95% confidence interval (CI): 2.12 - 5.53; P < 0.01), LMR ≥ 1.97 (HR 0.39, 95% CI: 0.21 - 0.72; P < 0.01) and mGPS 0 - 1 (HR 1.95, 95% CI: 1.20 - 3.16; P < 0.01). The OS of LMR ≥ 1.97 and mGPS 0 - 1 groups were significantly longer than those of LMR < 1.97 and mGPS 2 groups, respectively. We divided 159 patients into three groups, both LMR ≥ 1.97 and mGPS 0 - 1, either LMR ≥ 1.97 or mGPS 0 - 1 and both LMR < 1.97 and mGPS 2. The OS of both LMR < 1.97 and mGPS 2 was significantly shorter than the other two groups. After adjustment for age, sex, ECOG PS, sodium, alkaline phosphatase and NLR, multivariate analysis found both LMR < 1.97 and mGPS 2 as an independent poor prognostic combination in comparison with both LMR ≥ 1.97 and mGPS0-1 (HR 5.98, 95% CI: 2.64 - 13.5; P < 0.01).Conclusions: LMR and mGPS are independent prognostic markers for pulmonary adenocarcinoma with wild-type EGFR. Combination of LMR and mGPS can stratify patients according to prognosis.World J Oncol. 2018;9(1):13-20doi: https://doi.org/10.14740/wjon1084w.
机译:背景:中性粒细胞与淋巴细胞的比率(NLR),淋巴细胞与单核细胞的比率(LMR)和改良的格拉斯哥预后评分(mGPS)是基于宿主相关的全身性炎症反应的有用的预后标志物。它们已显示为包括非小细胞肺癌在内的各种癌症的独立预后生物标志物。然而,很少有证据表明特定的肺腺癌没有活跃的表皮生长因子受体(EGFR)突变。方法:我们回顾性审查了159例符合以下标准的患者:组织学或细胞学诊断的腺癌,确诊的野生型EGFR,我们于2007年7月至2017年3月在我院开始了一线细胞毒性化疗,并进入c期IIIB或IV期。我们通过NLR和LMR的最佳分界点以及mGPS 0-1与2比较了二分组之间的总生存(OS)。单因素和多因素Cox比例风险分析也检测到了OS的预后因素。结果:预后良好OS的因素,多变量分析检测到东部合作肿瘤小组的表现状态(ECOG PS)0-1(危险比(HR)3.43,95%置信区间(CI):2.12-5.53; P <0.01),LMR≥1.97(HR 0.39,95%CI:0.21-0.72; P <0.01)和mGPS 0-1(HR 1.95,95%CI:1.20-3.16; P <0.01)。 LMR≥1.97和mGPS 0-1组的OS分别显着长于LMR <1.97和mGPS 2组。我们将159例患者分为三组,LMR≥1.97和mGPS 0-1,LMR≥1.97或mGPS 0-1,LMR <1.97和mGPS2。OSR的LMR <1.97和mGPS 2均显着小于其他两组。在调整了年龄,性别,ECOG PS,钠,碱性磷酸酶和NLR之后,多变量分析发现LMR <1.97和mGPS 2与LMR≥1.97和mGPS0-1相比都是独立的不良预后组合(HR 5.98,95% CI:2.64-13.5; P <0.01)。结论:LMR和mGPS是具有野生型EGFR的肺腺癌的独立预后标志物。 LMR和mGPS的组合可以根据预后对患者进行分层。 2018; 9(1):13-20doi:https://doi.org/10.14740/wjon1084w。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号